FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Antibody topics
Antibodies
Recombinant
Monoclonal
Monoclonal Antibody
Differentiation
Polynucleotide
Nucleotide
Metabolism
Therapeutical
Combination Therapy
Bendamustine
Chemokine Receptor
Immune Response
Protein A Affinity Chromatography
Chromatograph

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Antibody patents



      
           
This page is updated frequently with new Antibody-related patent applications. Subscribe to the Antibody RSS feed to automatically get the update: related Antibody RSS feeds. RSS updates for this page: Antibody RSS RSS


Animal models and therapeutic molecules

Date/App# patent app List of recent Antibody-related patents
07/17/14
20140201856
 Animal models and therapeutic molecules patent thumbnailAnimal models and therapeutic molecules
The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
07/17/14
20140201854
 Animal models and therapeutic molecules patent thumbnailAnimal models and therapeutic molecules
The invention discloses methods for the generation of chimaeric human-non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.. .
07/17/14
20140200156
 Genes inducing agonistic effects by anti-c-met antibody treatment and drug screening method using the genes patent thumbnailGenes inducing agonistic effects by anti-c-met antibody treatment and drug screening method using the genes
Biomarkers for screening drugs reducing side effects of anti-c-met antibodies and a method of screening using the biomarkers, and more particularly, biomarkers commonly enhancing or reducing gene expression and a method of screening anti-c-met antibodies having reduced side effects using the biomarkers or a method of screening drugs that reduce side effects of anti-c-met antibodies.. .
07/17/14
20140199782
 Method to screen high affinity antibody patent thumbnailMethod to screen high affinity antibody
The current invention reports a method for producing an antibody comprising the steps of a) providing a plurality of hybridoma cells each expressing an antibody, b) determining the time dependent amount of said antibody bound to the respective antigen by surface plasmon resonance at different temperatures and different antibody concentrations, c) calculating with the time dependent amount determined in b) based on equations (ii) to (xiii) at least the thermodynamic parameters (i) standard association binding entropy (Δs°‡ass), (ii) standard dissociation binding entropy (Δs°‡diss), (iii) standard binding entropy (Δs°), (iv) free standard binding enthalpy (Δg°), (v) standard dissociation free binding enthalpy (Δg°‡diss), (vi) standard association free binding enthalpy (Δg°‡ass), (vii) −tΔs°, (viii) dissociation rate constant kd, (ix) equilibrium binding constant kd, and (x) association rate constant ka, d) selecting a hybridoma cell producing an antibody with at least two of the following: i) a standard association binding entropy of less than 10 j/k*mol, ii) an absolute standard dissociation binding entropy of 100 j/mol*k or more, iii) an absolute standard binding entropy of 100 j/mol*k or more, e) producing an antibody by cultivating said selected cell under conditions suitable for the expression of said antibody and recovering said antibody from the cells or/and the cultivation medium.. .
07/17/14
20140199729
 Method for reducing heterogeneity of antibodies and a process of producing the antibodies thereof patent thumbnailMethod for reducing heterogeneity of antibodies and a process of producing the antibodies thereof
The present disclosure relates to a method of reducing heterogeneity in antibodies during culturing, wherein the heterogeneity is due to proportion of charge variant of the antibody. The disclosure also comprises a process of growing cells in a cell culture system that results in antibodies with the reduced heterogeneity.
07/17/14
20140199714
 Method for detecting cancer cells metastasizing into sentinel lymph node patent thumbnailMethod for detecting cancer cells metastasizing into sentinel lymph node
A method for detecting a sentinel lymph node generating a microenvironment suitable for micrometastasis within the sentinel lymph node of carcinoma cells from a primary tumor or for detecting micrometastasis within the sentinel lymph node. A detecting agent is injected into the primary tumor, or tissue or a lymph node nearby the tumor, which allows the detecting agent to reach the sentinel lymph node by lymphatic circulation.
07/17/14
20140199711
 Method for determining glucagon-like peptide-1, and kit for use in said method patent thumbnailMethod for determining glucagon-like peptide-1, and kit for use in said method
Provided is a method of measuring the presence and/or the amount of glucagon-like peptide-1 (glp-1) in a sample, which method is characterized by comprising the step of treating the sample in advance with an acidic solution, and a kit of measuring the presence and/or an amount of glp-1 in a sample, the kit containing (a) the acidic solution, (b) an antibody specific to glp-1, and (c) an instruction manual.. .
07/17/14
20140199709
 Methods for diagnosing irritable bowel syndrome patent thumbnailMethods for diagnosing irritable bowel syndrome
The invention provides an elisa assay for the determination of serum mast cell β-tryptase levels using rabbit anti-tryptase as the capture antibody and alkaline phosphatase conjugated g3 as the detecting antibody. Luminescent substrate cpsd was used to enhance the assay sensitivity.
07/17/14
20140199331
 Bio-orthogonal drug activation patent thumbnailBio-orthogonal drug activation
The invention relates to a prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a prodrug kit comprising at least one prodrug and at least one activator, wherein the prodrug comprises a drug and a first bio-orthogonal reactive group (the trigger), and wherein the activator comprises a second bio-orthogonal reactive group.
07/17/14
20140199325
 Novel polypeptides and use thereof patent thumbnailNovel polypeptides and use thereof
The present invention provides a polypeptides capable of modulating tissue transglutarmnase-induced cell behaviour wherein the polypeptide comprises or consists of either (a) the amino acid sequence of a heparin-binding site of a tissue transglutaminase, or a functional fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant or derivative thereof or (b) an antibody capable of binding to a heparin-binding site of a lissue transglutaminase, or an antigen-binding fragment or derivative thereof. In one embodiment, the heparin-binding site of a tissue transglutaminase comprises or consists of an amino acid sequence of seq id no: 1, the invention further provides medical uses of the polypeptides of the invention and methods of treatment using the same..
07/17/14
20140199323
Monoclonal antibody
The present invention is related to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders which are caused by or associated with amyloid or amyloid-like proteins including amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as alzheimer's disease. The present invention provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to specific epitopes from a range of β-amyloid proteins.
07/17/14
20140199320
Modulators of the nlrp3 inflammasome il-1beta pathway for the prevention and treatment of acne
The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of il-1β, il-1 receptor type 1, nlrp3, asc, caspase-1 and cathepsin b with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of il-1β, il-1 receptor type 1, il-1 receptor type 2, nlrp3, asc and caspase-1. Similarly, an interfering rna or an antisense modulator of gene expression of il-1β, i l-1β receptor type 1, nlrp3, asc, caspase-1 and cathepsin b are provided for the prevention or treatment of acne..
07/17/14
20140199316
Methods of treating complications and disorders associated with g-csf administration
The present embodiments relate to novel uses of mpo inhibitors and inhibitors of mpo and e-selectin binding. In some embodiments, methods are provided for treating g-csf-induced vascular complications and associate tissue injury comprising administering to a subject in need thereof a compound that inhibits e-selectin receptor/ligand interaction or inhibits mpo activity.
07/17/14
20140199315
Sp35 antibodies and uses thereof
Endogenous sp35 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination (negative regulator). Molecules that block endogenous sp35 function, such anti-sp35 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction.
07/17/14
20140199312
Ddr1-binding agents and methods of use thereof
The present invention relates to ddr1 binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind to an extracellular domain of ddr1 and modulate ddr1 activity.
07/17/14
20140199311
Pharmaceutical composition for treatment and/or prophylaxis of cancer
This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a caprin-1 protein, the antibody comprising a heavy chain variable region comprising complementarity determining regions of seq id nos: 5, 6, and 7 and a light chain variable region comprising complementarity determining regions of seq id nos: 9, 10, and 11, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising the same as an active ingredient..
07/17/14
20140199309
Fragment of secreted heat shock protein-90alpha (hsp90alpha) as vaccines or epitope for monoclonal antibody drugs or target for small molecule drugs against a range of solid human tumors
The invention provides methods for treating hif-1α-overexpressing human tumors, inhibiting hif-1α-overexpressing tumor invasion and preventing tumor metastasis, and/or promoting tumor prophylaxis, using various types of inhibitors against the hsp90α from the tumors.. .
07/17/14
20140199308
Compositions and methods to enhance the immune system
The invention relates to the field of molecular medicine. In particular, it relates to compositions and methods to enhance the clearance of aberrant cells, e.g.
07/17/14
20140199307
Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
The present invention relates to a method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by the administration of a cd19xcd3 bispecific antibody to said patient comprising determining the ratio of b cells to t cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient or determining the total b cell count of said patient, wherein a total b cell count of less than about 50 b cells per microliter of peripheral blood is indicative for a risk of potential adverse effects for said patient. Accordingly, the present invention relates a method (dosage regimen) for administering a cd19xcd3 bispecific antibody to a human patient having a b:t cell ratio of about 1:5 or lower and/or a total b cell count of less than about 50 b cells per microliter of peripheral blood, comprising (a) administering a first dose of said antibody for a first period of time; and consecutively (b) administering a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose.
07/17/14
20140199301
Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2/kdr)
Phage displayed recombinant antibody library was developed and the library was screened against vegfr-2. After screening and elisa experiments two recombinant antibodies showing binding properties to vegfr-2 was obtained.
07/17/14
20140199297
Triterpene glycoside and triterpene compositions and methods of using same
In the present invention, different strategies are used to improve the bioavailability of triterpene glycosides and triterpenes including, for example, (a) a covalent approach involving modification with polyethylene glycol and (b) a formulation approach involving non-covalent encapsulation in antibody targeted pol(dl-lactic acid) nanoparticles.. .
07/17/14
20140199293
Humanized antibody compositions and methods for binding lysophosphatidic acid
Compositions and methods for making and using humanized anti-lpa monoclonal antibodies, and fragments and derivatives thereof, are described.. .
07/10/14
20140194601
Antibody drug conjugates (adc) that bind to 161p2f10b proteins
Antibody drug conjugates (adc's) that bind to 161p2f10b protein are described herein. 161p2f10b exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in table i.
07/10/14
20140194599
Anti-human interleukin-20 antibodies
Anti-human il20 monoclonal antibodies that can reduce il20 mediated activation of both il20r1/il20r2 and il22r1/il20r2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders..
07/10/14
20140194596
Dual specificity antibody fusions
The present invention provides dual specificity antibody fusion proteins comprising an antibody fab or fab′ fragment with specificity for an antigen of interest, said fragment being fused to at least one single domain antibody which has specificity for a second antigen of interest.. .
07/10/14
20140194308
Use of myelin basic protein as a novel genetic factor for rheumatoid arthritis
A method of testing for rheumatoid arthritis, comprising detecting an autoantibody to myelin basic protein in a biological sample from a subject. A test kit for rheumatoid arthritis, comprising myelin basic protein.
07/10/14
20140194304
Process for ultra-sensitive quantification of target analytes in complex biological systems
Antibody-free processes are disclosed that provide accurate quantification of a wide variety of low-abundance target analytes in complex samples. The processes can employ high-pressure, high-resolution chromatographic separations for analyte enrichment.
07/10/14
20140193908
Sequential antibody therapy
The invention provides a blocking ligand specific for ctla-4 and a vascular targeting ligand/il-2 complex, for sequential use in inhibiting the growth of tumour cell. .
07/10/14
20140193899
Monoclonal antibodies to fibroblast growth factor receptor 2
The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.. .
07/10/14
20140193874
Novel biomarker for diagnosis of lung cancer
Disclosed are a composition for diagnosis of lung cancer including an antibody specific to gpi specific phospholipase d1 (gpld1) protein, which is an effective biomarker for early diagnosis of lung cancer, and a composition for diagnosis of lung cancer including a primer or probe specific to a nucleic acid encoding the gpld1 protein. The lung cancer diagnostic marker may be effectively used in early diagnosis of lung cancer and also, is very useful for evaluating progression of a disease and prognosis before and after treatment of the same..
07/10/14
20140193855
Methods and compositions for determining the purity of chemically synthesized nucleic acids
This application describes an antibody that specifically binds to a synthetic oligomer (e.g., an oligonucleotide or oligopeptide) having a organic protecting group covalently bound thereto, which antibody does not bind to that synthetic oligomer when the organic protecting group is not covalently bound thereto. Methods of making and using such antibodies are also disclosed, along with cells for making such antibodies and articles carrying immobilized oligomers that can be used in assay procedures with such antibodies..
07/10/14
20140193840
Chromatography filter paper-based elisa
A chromatography filter paper-based elisa includes following steps: providing a chromatography filter paper plate provided with a plurality of independent hydrophilic regions defined by at least one hydrophobic region; immobilizing an antigen of a sample onto one of the hydrophilic regions of the chromatography filter paper plate; and detecting the antigen with an elisa process, wherein an antibody used in the elisa process is a monoclonal antibody. The present invention has advantages in lower amount of loaded sample, higher sensitivity and rapid analysis in comparison to conventional elisa..
07/10/14
20140193838
Method for measuring sialic acid in immunoglobulin g and immunoglobulin g anti-double-stranded dna antibodies
A method for measuring the amount of sialic acid in immunoglobulin g and immunoglobulin g anti-ds dna antibodies is disclosed. The method for measuring the amount of sialic acid in immunoglobulin g in the present invention uses culture fluid, blood, plasma, or serum to directly measure the amount of sialic acid in immunoglobulin g.
07/10/14
20140193832
Detection of prostate cancer using psa glycosylation patterns
The present invention features novel methods for determining if a subject has prostate cancer. The present invention is based on the development of lectin immunosorbant assays which analyze α2,6-linked sialylation of total serum psa by sambucus nigra lectin (sna) and α2,3-linked sialylation of total and free serum psa.
07/10/14
20140193514
Method for the treatment of cancer
The invention describes a method to treat an extracorporeally body fluid. The body fluid can include, for example, blood, cerebral spinal fluid and lymph.
07/10/14
20140193446
Biodegradable high-efficiency dengue vaccine, method for making the same, and pharmaceutical composition comprising the same
The present invention is related to a biodegradable high-efficiency dengue vaccine, a method for making the same, and a pharmaceutical composition comprising the same. The biodegradable high-efficiency dengue vaccine comprises a biodegradable nanocomplex with electric properties holding a dengue viral protein inside.
07/10/14
20140193441
Method of administering porcine b-domainless fviii
The present invention provides a method of administering porcine b-domainless factor viii (obi-1) to a patient having factor viii deficiency to provide more rapid and effective protection against bleeding episodes, compared to formerly available methods, or to provide more effective protection to such patients during non-bleeding periods. This invention is based on the discovery that the recombinant b-domainless porcine fviii, termed obi-1, has greater bioavailability compared to the natural porcine fviii partially purified from porcine plasma, termed hyate:c.
07/10/14
20140193434
Pharmaceutical composition for treatment and/or prophylaxis of cancer
It is intended to identify a cancer antigenic protein specifically expressed on the surface of cancer cells and to provide an antibody targeting the antigenic protein and use of the antibody as a therapeutic and/or preventive agent for cancer. The present invention provides an antibody or a fragment thereof which has immunological reactivity with a caprin-1 protein, the antibody comprising a heavy chain variable region comprising amino acid sequences of seq id nos: 5, 6, and 7 and a light chain variable region comprising amino acid sequences of seq id nos: 9, 10, and 11, and a pharmaceutical composition for treatment and/or prevention of cancer, comprising this antibody or fragment as an active ingredient..
07/10/14
20140193433
Bcma-based stratification and therapy for multiple myeloma patients
The present invention relates to methods for the stratification of a multiple myeloma (mm) patient comprising determining whether or not b-cells, preferably malignant b-cells of said patient express bcma protein on their surface. Also, methods for selecting an antibody-based multiple myeloma (mm) therapy is based on whether or not bcma is expressed on the cell surface of b-cells, preferably malignant b-cells of a patient.
07/10/14
20140193432
Anti-hdlk-1 antibody having an antitumor activity in vivo
The present invention provides: antibodies specifically reacting against hdlk-1 and having anti-tumor activity in vivo (anti-hdlk-1 antibodies, and in particular, humanized anti-hdlk-1 antibodies); fragments of the antibodies; hybridomas that produce the antibodies; a complex of the antibody or antibody fragment and an agent; a pharmaceutical composition, a tumor therapeutic agent, a tumor diagnostic agent and an agent for inducing apoptosis in tumor cells, each of which comprises the aforementioned antibody or the like; a method for treating tumor, a method for detecting tumor, a method for inducing apoptosis in tumor cells, a kit for detecting and/or diagnosing tumor and a kit for inducing apoptosis in tumor cells, each of which comprises the use of the aforementioned antibody or the like; etc.. .
07/10/14
20140193431
Anti-c-met antibody having hgf activity and use thereof
Disclosed are a human antibody comprising a human complementarity-determining region (cdr), which binds specifically to c-met, and a framework region (fr), a polynucleotide encoding the human antibody, an expression vector comprising the polynucleotide, a transformant transformed with the expression vector, a method of producing the human antibody b7 by culturing the transformant, a wound healing composition comprising the human antibody as an active ingredient, a cell regeneration composition comprising the antibody as an active ingredient, and a drug conjugate comprising a drug linked to the human antibody. The c-met-specific human antibody can function as an hgf mimic that can be used as a wound healing composition.
07/10/14
20140193428
Human cytomegalovirus neutralizing antibodies and use thereof
The invention relates to neutralizing antibodies, and antibody fragments thereof, having high potency in neutralizing hcmv, wherein said antibodies and antibody fragments are specific for one, or a combination of two or more, hcmv gene ul products. The invention also relates to immortalized b cells that produce, and to epitopes that bind to, such antibodies and antibody fragments.
07/10/14
20140193423
Diagnosis and treatment of viral diseases
This disclosure relates to methods of diagnosing a viral disease in a patient by identifying one or more virus-specific elements or a patient antibody to a virus-specific element, as well as to kits for diagnosing a viral disease in a patient. The disclosure further relates to methods of monitoring disease progression and/or the efficacy of therapy by measuring the levels of a virus-specific element in a sample from a patient.
07/10/14
20140193422
Fully human antibodies against human 4-1bb
Fully human antibodies and antigen-binding portions thereof that bind to human 4-1bb and that allow binding of human 4-1bb to a human 4-1bb ligand. In one aspect, the antibody is an igg4 antibody.
07/10/14
20140193421
Anti-human xcr1 antibodies
An object of the present invention is to provide a monoclonal antibody binding to human xcr1, wherein the antibody binds to linear or discontinuous epitopes which comprise at least three amino acids selected from the group consisting of the 8th, 11th, 12th, 13th, 14th, 16th, 17th, 22nd, 23rd, 176th, and 177th amino acids in the amino acid sequence of seq id no: 91.. .
07/10/14
20140193420
Diagnosis and treatment of cancer using anti-itm2a antibody
Disclosed is a monoclonal antibody binding to an itm2a protein. This antibody is useful in the diagnosis, prevention, and treatment of cancer such as ewing's sarcoma, t cell leukemia, t cell lymphoma, acute myeloid leukemia, b cell tumor, and multiple myeloma.
07/10/14
20140193418
Anti-human epo receptor antibodies and methods of use
Herein is reported an antibody that specifically binds to human epo receptor, wherein the antibody binds to epo receptor fragment lpgpggsvdiv (seq id no: 01) but that does not specifically bind to a protein obtainable from human endothelial cells that has a molecular weight of about 66 kd.. .
07/10/14
20140193417
Membrane transporter napi2b (scl34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
The present disclosure relates generally to the membrane transporter napi2b (slc34a2) as a target for therapy, including immunotherapy, and particularly cancer therapy. The slc34a2 epitope peptide encompassing amino acids 312-340 of slc34a2 has been identified as an ovarian cancer epitope using the monoclonal antibody mx35.
07/10/14
20140193413
Antibodies binding to phosphorylcholine (pc) and/or pc conjugates
The present disclosure relates to an antibody or antibody fragment capable of binding to phosphorylcholine and/or a phosphorylcholine conjugate, wherein the antibody or antibody fragment comprises a variable heavy chain (vh) domain and/or a variable light chain (vl) domain, and wherein (a) the vh domain comprises complementarity determining regions (cdrs) selected from the group consisting of: a cdr1 sequence having identity to the sequence of seq id no: 7; a cdr2 sequence having identity to the sequence of seq id no: 8; and a cdr3 sequence having identity to the sequence of seq id no: 9 or 10; and/or (b) the vl domain comprises cdrs selected from the group consisting of: a cdr4 sequence having identity to the sequence of seq id no: 11; a cdr5 sequence having identity to the sequence of seq id no: 12; a cdr6 sequence having identity to the sequence of seq id no: 13.. .
07/10/14
20140193411
Multimeric constructs
Multimeric fusion proteins of an ig-like domain of flt-1 are rendered functional by inclusion of a linker moiety. Vectors encoding the fusion proteins and host cells expressing the fusion proteins can be used therapeutically to block neovascularization in individuals with pathological conditions related to neovascularization.
07/10/14
20140193408
Soluble proteins for use as therapeutics
The present invention relates to improved binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble protein, comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first single chain polypeptide comprising: (a) an antibody heavy chain sequence having vh, ch1, ch2, and ch3 regions; and (b) a monovalent region of a mammalian binding molecule fused to the vh region; and (ii) a second single chain polypeptide comprising: (c) an antibody light chain sequence having a vl and cl region; and (d) a monovalent region of a mammalian binding molecule fused to the vl region; characterised in that each pair of vh and vl cdr sequences has specificity for an antigen, such that the total valency of said soluble protein is six.
07/10/14
20140193407
Drug fusions and conjugates
The present invention relates to drug fusions that have improved serum half lives. These fusions and conjugates comprise polypeptides, immunoglobulin (antibody) single variable domains and glp and/or exendin molecules.
07/10/14
20140193404
Glycosylated antibodies
The invention provides an antibody comprising human igg1 or igg3 heavy chain constant domains that are glycosylated with a sugar chain at asn297, said antibody being characterized in that the amount of fucose within said sugar chain is at least 99%, and in addition the amount of ngna is 1% or less and/or the amount of n-terminal alpha 1,3 galactose is 1% or less, and uses thereof.. .
07/10/14
20140193403
Epitopes of il-17a and il-17f and antibodies specific thereto
The present invention relates neutralising epitopes of il-17a and il-17f and antibodies which bind those epitopes. The present invention also relates to the therapeutic uses of the antibody molecules and methods for producing them..
07/10/14
20140193398
Polymalic acid-based nanobiopolymer compositions
Nanobiopolymeric conjugates based on biodegradable, non-toxic and non-immunogenic poly (β-l-malic acid) pmla covalently linked to molecular modules that include morpholino antisense oligonucleotides (aona), an sirna or an antibody specific for an oncogenic protein in a cancer cell, and an antibody specific for a transferrin receptor protein, are provided. Methods for treating a cancer in subject with nanobiopolymeric conjugates are described..
07/10/14
20140193359
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (hcf) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a ph of about 5.2.
07/10/14
20140193334
Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof
Acridine containing cisplatin compounds have been disclosed that show greater efficacy against cancer than other cisplatin compounds. Methods of delivery of those more effective cisplatin compounds to the nucleus in cancer cells is disclosed using one or more amino acids, one or more sugars, one or more polymeric ethers, c1-6alkylene-phenyl-nh—c(o)—r15, folic acid, αvβ3 integrin rgd binding peptide, tamoxifen, endoxifen, epidermal growth factor receptor, antibody conjugates, kinase inhibitors, diazoles, triazoles, oxazoles, erlotinib, and/or mixtures thereof; wherein r15 is a peptide..
07/03/14
20140188033
Drug delivery using a sacrificial host
Implantable drug-doped component, e.g., a cochlear implant, including host material, a host-embedded drug, a sacrificial material integrated with the host. Sacrificial material facilitates release of drug from the component.
07/03/14
20140187756
Methods of preparing antibody-active agent conjugates
The invention provides methods for preparing an antibody-active agent conjugate. The conjugate comprises an antibody, a cysteine residue of an amino acid motif that can be recognized by an isoprenoid transferase located at or after the carboxy-terminus of the antibody, an isoprenoid unit operably linked to the cysteine residue, and an active agent.
07/03/14
20140187749
Single unit chromatography antibody purification
The present invention relates to a method for the purification of antibodies from a protein mixture produced in a bioreactor, at least comprising the steps of intermediate purification and polishing, wherein the intermediate and polishing step comprises in-line anion exchange chromatography (aex) treatment and mixed mode chromatography (mimo) treatment in flow through mode. The present invention further relates to a single operational unit comprising both an anion exchange chromatography part and a mixed mode chromatography part, which are serially connected, wherein the unit comprises an inlet at the upstream end of the anion exchange chromatography part and an outlet at the downstream end of the mixed mode chromatography part and wherein the unit also comprises an inlet between the anion exchange chromatography part and the mixed mode chromatography part..
07/03/14
20140187445
Antibody-based arrays for detecting multiple signal transducers in rare circulating cells
The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.. .
07/03/14
20140186943
Nucleic acids encoding a human monoclonal antibody that specifically binds to il-1a
Fully human monoclonal abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for il-1α and (ii) a constant region that is effective at both activating the complement system though c1q binding and binding to several different fc receptors.. .
07/03/14
20140186933
Method and device for detecting prior drug use, taking inflammation into account to increase test's specificity and reduce false positives
This method and device detects past use of drugs of abuse when the drug substance and its metabolites are no longer present in the body, based on the detection of the antibodies formed in response to said drug, and persist even after this drug and its metabolites are cleared from the body. False positive rate is reduced by screening out subjects with heightened inflammatory state.
07/03/14
20140186891
Polynucleotides encoding il-31 monoclonal antibodies
The invention provides humanized mouse anti-human il-31 antibodies and antibody fragments that are capable of binding il-31 and thereby neutralizing, inhibiting, limiting, or reducing the proinflammatory or pro-pruritic effects of il-31.. .
07/03/14
20140186889
Antibody generation from plasmacytoma-prone transgenic animals
Certain transgenic animals which are prone to the rapid cell division of their antibody-secreting cells have superior properties for the generation of monoclonal antibodies. Not only can their antibody producing cells can be made into hybridomas with superior growth to hybridomas from non-prone animals, but the antibody producing cells themselves can be cultured directly without cell fusion or further manipulation.
07/03/14
20140186867
Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
A composition comprising a main species her2 antibody that binds to domain ii of her2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed..
07/03/14
20140186863
Method for detecting pancreatic disease marker
The present invention relates to a method for detecting a marker for pancreatic disease for obtaining highly reliable results while reducing the risk of complications. It also relates to a method for a detecting a marker for pancreatic disease comprising: measuring the concentration of a marker for pancreatic disease in duodenal juice that is collected from a subject and contains spontaneously discharged pancreatic juice, by a measurement method including detecting antigen or antibody immobilized on a solid phase using an antigen-antibody reaction, and the aforementioned method for detecting a marker for pancreatic disease further including judging the subject to have the possibility of being afflicted with a pancreatic disease in the case the concentration of the marker for pancreatic disease is equal to or greater than a prescribed threshold value..
07/03/14
20140186850
Reagents and methods for bispecific antibody-based binding of target molecules
The invention provides methods for delivery of payloads to targets in samples using non-sterically hindered complexes. The invention further provides reagents and kits for practicing the methods of the invention.
07/03/14
20140186434
Anti-tumor necrosis factor alpha (tnf-a) antibody used as a targeting agent to treat arthritis and other diseases
This invention describes the use of anti-tnf-a antibody as a targeting agent attached to liposomes incorporating anti-inflammatory drugs to treat arthritis and other inflammatory diseases. A variety of steroidal and non-steroidal drugs and disease modifying drugs and other anti-inflammatory compounds may be incorporated into the anti-tnf-a coated liposomes.
07/03/14
20140186377
Prostaglandin e2 binding proteins and uses thereof
The present invention encompasses prostaglandin e2 (pge2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, cdr grafted and humanized.
07/03/14
20140186373
Antibody formulation
Anti-baffr antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation.
07/03/14
20140186368
Methods of administering anti-tnfalpha antibodies
Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
07/03/14
20140186360
Phosphorylcholine conjugates and corresponding antibodies
In subjects with hypertension, increases in intima-media thickness (imt) at four years were less in subjects also having high autoantibodies particularly igm, to phosphorylcholine. The presence or absence of autoantibodies, particularly igm, against phosphrylcholine is thus related to an increased or decreased risk of developing ischemic cardiovascular diseases.
07/03/14
20140186359
Pharmaceutical composition for treatment and/or prophylaxis of cancer
This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof as a therapeutic and/or preventive agent for cancer. More specifically, the present invention provides an antibody, or a fragment thereof which has immunological reactivity with a partial caprin-1 polypeptide consisting of the amino acid sequence shown by seq id no: 5 or an amino acid sequence having 80% or higher sequence identity to the amino acid sequence, and a pharmaceutical composition for treatment and/or prevention of cancer comprising the same as an active ingredient..
07/03/14
20140186356
Combination of a c-met antagonist and an aminoheteroaryl compound for the treatment of cancer
The invention also relates to a composition comprising an antibody antagonist to c-met and an aminoheteroaryl compound, particularly as a medicament. The present invention also comprises a pharmaceutical composition comprising said anti c-met antibody and said aminoheteroaryl compound as combination products for simultaneous, separate or sequential use.
07/03/14
20140186355
Nucleic acids encoding antibody molecules which bind il-17a and il-17f
The invention relates to antibody molecules having specificity for antigenic determinants of both il-17a and il-17f, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.. .
07/03/14
20140186352
Anti-granulysin antibodies and methods of use thereof
An anti-granulysin antibody, or an scfv or fab fragment thereof, capable of binding to an epitope region from r64 to r113 of granulysin and capable of neutralizing an activity of granulysin. The antibody may contain a sequence selected from the sequences of seq id no:82 to seq id no:195, or the antibody may contain a sequence selected from the sequences of seq id no:39 to seq id no:76.
07/03/14
20140186349
Human cdr-grafted antibody and antibody fragment thereof
A human cdr-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of human cc chemokine receptor 4 (ccr4) but does not react with a human blood platelet; a human cdr-grafted antibody or the antibody fragment thereof which specifically reacts with the extracellular region of ccr4 and has a cytotoxic activity against a ccr4-expressing cell; and a medicament, a therapeutic agent or a diagnostic agent comprising at least one of the antibodies and the antibody fragments thereof as an active ingredient.. .
07/03/14
20140186348
Humanized and chimeric anti-properdin antibodies
An isolated anti-properdin antibody or antigen binding portion thereof includes a heavy chain variable domain including the 3cdrs in seq id no: 1 and light chain variable domain including the 3cdrs in seq id no: 9.. .
07/03/14
20140186345
Method of administering an antibody
Disclosed is a method for treating a human having a disease associated with leukocyte infiltration of mucosal tissues, comprising administering to said human an effective amount of a human or humanized immunoglobulin or antigen-binding fragment thereof having binding specificity for α4β7 integrin. Preferably, no more than about 8 mg immunoglobulin or fragment per kg body weight are administered during a period of about one month..
07/03/14
20140186343
Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
A composition comprising a main species her2 antibody that binds to domain ii of her2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed..
07/03/14
20140186342
Compositions and methods for diagnosing and treating cancer
An isolated antibody that specifically binds to an extracellular domain of human ddr2 and has a therapeutic effect on a solid tumor is described. Also described is a method of treating cancer, the method comprising administering to a patient having a solid tumor an antibody of the present disclosure in a therapeutically effective amount..
07/03/14
20140186339
Compositions and methods for treating ocular diseases and conditions
The present invention relates to compositions and methods for prevention and treatment of ocular diseases and conditions, particularly glaucoma and ocular hypertension. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against the bioactive lipid, sphingosine-1-phosphate, and its variants, which moieties are capable of decreasing the effective concentration of bioactive lipid being targeted.
07/03/14
20140186337
Antitumors combinations containing antibodies recognizing specifically cd38 and bortezomib
Pharmaceutical composition comprising an antibody specifically recognizing cd38 and bortezomib.. .
07/03/14
20140186336
Methods of treating pterygium
Methods for treating pterygium recurrence following pterygiectomy, and for treating keloid recurrence, following surgical removal of the keloid, are disclosed. The methods include administering an anti-vegf agent (e.g., antibody (e.g., bevacizumab) or small molecule inhibitor of vegf signaling), or a combination therapy that includes co-administering an anti-vegf agent, with an anti-inflammatory steroid and/or a non-steroidal anti-inflammatory drug (nsaid) to a subject..
07/03/14
20140186334
Surface, anchored fc-bait antibody display system
The present invention provides, in part, an antibody display system that simultaneously uses a secretion and a display mode. A bait complexed with a monovalent antibody fragment can be expressed on the surface of the host cell wherein the fragment may be assayed for antigen binding while full antibody is simultaneously secreted from the host cell.
07/03/14
20140186293
Immunoglobulin-bound extracellular vesicles and uses thereof
Provided are methods of isolating igg-bound (e.g., igg-bound or protein g-recognized igg-bound) extracellular vesicles from a sample containing a biological fluid from a subject, where the igg (e.g., igg2 or protein g-recognized igg) is bound to an antigen present on the surface of the extracellular vesicle and the igg (e.g., igg2 or protein g-recognized igg) is an endogenous antibody. Also provided are methods of diagnosing a cancer in a subject that include detecting the presence of one or more tumor antigens in an isolated igg-bound (e.g., igg2-bound or protein g-recognized igg-bound) extracellular vesicle, and methods of treating a subject that include administering one or more cancer therapeutics to a subject having an igg-bound (e.g., igg2-bound or protein g-recognized igg-bound) extracellular vesicle that contains one or more tumor antigens..


Popular terms: [SEARCH]

Antibody topics: Antibodies, Recombinant, Monoclonal, Monoclonal Antibody, Differentiation, Polynucleotide, Nucleotide, Metabolism, Therapeutical, Combination Therapy, Bendamustine, Chemokine Receptor, Immune Response, Protein A Affinity Chromatography, Chromatograph

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Antibody for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Antibody with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.4144

4647

3 - 0 - 102